Artery administration tube

Abstract

The invention discloses an arterial drug delivery tube, which belongs to the field of medical instruments and comprises a catheter body, a drug delivery tube, a drug delivery tube, a drug delivery tube and a drug delivery tube body, and the catheter body is provided with a near end, a far end and a main cavity channel between the near end and the far end; the blocking unit is arranged at the far end of the catheter body, the blocking unit is configured to be capable of being operated in the blood vessel from a first state to a second state, and in the second state, the blocking unit at least partially abuts against the blood vessel wall and blocks blood flow of the corresponding blood vessel area; an annular plugging chamber is formed in the blood vessel at the position corresponding to the plugging unit in the axial direction of the catheter body; the exudation holes allow fluid in the main cavity channel to penetrate through the inner blood vessel environment of the catheter wall of the catheter body to exudate; and when the plugging unit is in the second state, the flowing path of the fluid seeping through the seeping hole is at least partially restrained in the annular plugging cavity by the plugging unit. Through the arrangement, a plugging pipe section can be constructed in a blood vessel, so that the drug residence time is prolonged, and the drug action area is limited.

Description

TECHNICAL FIELD

[0001] The present application belongs to the technical field of medical devices, and particularly relates to an arterial drug delivery tube. BACKGROUND

[0002] In preclinical studies of arterial injection for treating ischemic stroke and related cerebrovascular diseases, it is necessary to establish a reliable ischemia-reperfusion model of experimental animals (such as rats and mice) to evaluate neuroprotective strategies, explore pathological mechanisms, and test new therapies. One of the core goals of such experiments is to accurately and efficiently deliver neuroprotective agents, anti-inflammatory drugs, and other therapeutic drugs to the infarct area that has suffered ischemic injury after successful thrombectomy and restoration of blood flow, and to ensure that the drugs achieve sufficient local retention and adequate dispersion in the area, thereby maximizing their therapeutic effect.

[0003] The conventional practice in experimental animal operations is to infuse drugs into the internal carotid artery direction through a simple catheter or cannula inserted into the residual end of the external carotid artery after removing the blocking wire and restoring blood flow. This method has significant drawbacks: the injected drugs will immediately flow away with the restored carotid blood flow, the effective retention time in the target cerebrovascular region (such as the ischemic brain area) is extremely short, and the contact between the drugs and the vascular endothelium and ischemic tissue is insufficient, with poor dispersion. This results in a much lower actual exposure concentration and exposure time of the drugs in the local lesion than theoretically expected, severely affecting the bioavailability of the therapeutic agent and the reliability of the experimental results.

[0004] Therefore, there is an urgent need in the art for an apparatus specifically designed for arterial drug delivery in experimental animal models of cerebral ischemia-reperfusion. The apparatus needs to temporarily create a relatively isolated fluid environment inside the target vascular segment, forcing the injected drug solution to remain in the segment for a sufficient period of time, and to achieve sufficient and controllable contact and dispersion with the vascular wall and target tissue perfused through collateral circulation, to simulate and optimize the therapeutic conditions of local drug delivery and improve the effectiveness and scientificity of preclinical studies. SUMMARY

[0005] To overcome the problems presented in the background art, the present application adopts the following technical solutions:

[0006] An arterial drug delivery tube, comprising: a catheter body having a proximal end, a distal end, and a main lumen therebetween; a blocking unit provided at the distal end of the catheter body, and the blocking unit is configured to be operable from a first state to a second state in the blood vessel, in the second state, the blocking unit at least partially abuts against the blood vessel wall and blocks the blood flow of the corresponding blood vessel region; a plurality of exudation holes provided on the wall of the catheter body, the exudation holes are configured to allow the fluid in the main lumen to exude into the intravascular environment through the wall of the catheter body; When the occlusion unit is in the first state, the outer diameter of the catheter body is smaller than the inner diameter of the blood vessel, so as to allow the catheter body to move smoothly from the arterial stump to the drug release target area; when the occlusion unit is in the second state, the flow path of the fluid seeping through the exudate hole is at least partially constrained by the occlusion unit. As the fluid drug gradually passes through the tube wall and enters the intravascular environment, the drug first moves in the annular occlusion chamber and gradually diffuses outward through the blood vessel wall.

[0007] The elastic balloon is specifically an annular balloon, which is constructed as part of the wall of the catheter body. In the first state, the outer diameter of the catheter body is substantially uniform.

[0008] By embedding an elastic balloon within the catheter wall, making it flush with the outer wall of the catheter when not inflated, a smooth and continuous surface is formed. The distal end of the catheter body has a closed, smooth, blunt-shaped structure. This prevents the catheter tip from puncturing or damaging blood vessels, especially small and fragile vessels, during travel. The exudation orifice is located on the catheter body within the axial section corresponding to the annular occlusion chamber.

[0009] Furthermore, the occlusion unit includes at least two elastic balloons spaced apart along the axial direction of the catheter body. When the elastic balloons are in their natural state, the occlusion unit is in a first state, and when the elastic balloons are inflated, the occlusion unit is in a second state. When at least two elastic balloons are in the second state, an annular occlusion chamber is formed between the at least two elastic balloons, the inner wall of the blood vessel, and the outer wall of the catheter body, and the exudation hole is in fluid communication with the annular occlusion chamber.

[0010] Furthermore, the at least two elastic balloons are fluidly connected to a first connecting tube, the end of the first connecting tube opposite to the elastic balloons extending towards the proximal end of the catheter body and remaining outside through the wall of the catheter body.

[0011] Furthermore, the seepage hole is specifically a guide hole with a one-way flow restriction structure. The one-way flow restriction structure is configured to allow fluid to seep out from the main cavity through the guide hole and to inhibit external fluid from flowing back into the main cavity through the guide hole. The one-way flow restriction structure is specifically a one-way valve.

[0012] The one-way valve design ensures unidirectional delivery of the fluid medication. This prevents backflow of blood and impurities, maintains the patency of the main lumen and exudate orifice, and sustains the positive pressure established within the annular occlusion chamber during injection. This contributes to improved delivery efficiency and drives the medication to diffuse more effectively into the vessel wall tissue.

[0013] Furthermore, the main cavity is provided with two axially fixed limiting cylinders, the axial positions of the two limiting cylinders corresponding to the axial positions of the two elastic balloons, and the limiting cylinders are configured to restrict the corresponding elastic balloons from collapsing into the main cavity when inflated.

[0014] An axially fixed rigid or semi-rigid limiting cylinder is used as an internal support framework. When the elastic balloon inflates, its inner side is physically blocked by the limiting cylinder, and the inflation force is directed towards the vessel wall on the outer side of the main lumen, thus ensuring the patency of the central channel of the main lumen.

[0015] Furthermore, the two limiting cylinders are spaced apart from each other, and a drug storage and delivery area is formed in the main cavity section between the two limiting cylinders.

[0016] The space between the two limiting cylinders is structured into a defined second annular chamber.

[0017] Furthermore, a fluid-push balloon is disposed between the two elastic balloons, and the fluid-push balloon partially passes through the two limiting cylinders; the outer diameter of the fluid-push balloon in its natural state is smaller than the inner diameter of the limiting cylinder, and the fluid-push balloon is fluidly connected to a second connecting tube; during the process of the fluid-push balloon deforming from its natural state to an inflated state, its outer wall abuts against the inner wall of the limiting cylinder, and a second annular chamber not communicating with the proximal end of the catheter body is formed between the two limiting cylinders; the volume of the second annular chamber gradually decreases as the fluid-push balloon continues to deform towards the inflated state, and the drug solution is pushed into the annular sealing chamber.

[0018] Furthermore, it also includes a method for intravascular local drug delivery using a delivery tube, which includes the following steps: S1. Deliver the distal end of the catheter body to the target vascular region; S2. The elastic balloon is inflated by filling the first connecting tube with fluid, thereby forming an annular occlusion chamber with the blood vessel wall inside the blood vessel; S3. Injecting a fluid agent into the second annular cavity through the main cavity; S4. The fluid-inflating balloon disposed in the second annular chamber is inflated by filling the second connecting tube with fluid. The inflation of the fluid-inflating balloon performs the following operations in sequence: S401. The outer wall of the push balloon contacts and seals the inner walls of the two limiting cylinders, isolating the second annular chamber from the other parts of the main cavity; S402. The continuing to expand liquid-push balloon pushes the fluid agent sealed in the second annular chamber through the exudation hole into the annular sealing chamber; S403. The further expanded balloon contacts and expands the outer wall of the catheter body, thereby compressing the volume of the annular occlusion chamber and promoting the diffusion of the fluid agent through the blood vessel wall.

[0019] Furthermore, after the inflation of the propellant balloon in operation S403, the procedure further includes: maintaining the propellant balloon in the inflated state for a preset time to maintain the compression state of the annular occlusion chamber.

[0020] This setup adds a pressure-holding step after the compression step. By maintaining the inflation of the balloon, the annular occlusion chamber is continuously compressed, creating a continuous and stable pressure gradient on the outer side of the vessel wall. This allows for more effective drug diffusion along the pressure gradient, significantly increasing the drug's penetration depth and retention in the target tissue.

[0021] Furthermore, after step S403, the procedure further includes: contracting the fluid-injecting balloon and then inflating it again to repeat operations S402 and S403 at least once.

[0022] By introducing a pulsed permeation-enhancing step, after completing one push-compression-holding cycle, the push balloon is reset, allowing a small amount of medication to be replenished to the second annular chamber through the main channel again, and then the push and compression process is repeated.

[0023] The beneficial effects of this invention are: 1. This invention comprises an occlusion unit capable of constructing an annular occlusion chamber within a blood vessel, and a propellant balloon positioned within the main lumen. Through the synergistic action of the occlusion unit and the propellant balloon, it further promotes drug penetration into the vessel wall while achieving spatial isolation. First, the occlusion unit constructs a sealed space in the target vessel segment to isolate it from blood flow. Then, as the propellant balloon expands, it automatically and sequentially achieves the following: formation of a second annular chamber – ejection of the drug within the second annular chamber – compression of the annular occlusion chamber. By actively reducing the volume of the annular occlusion chamber, a transient and directional hydrostatic pressure is generated locally. This pressure directly acts on the drug distributed within the annular occlusion chamber, forcing it to accelerate its penetration into the tissue outside the vessel wall. This mechanism fundamentally solves the problems of limited drug diffusion depth and insufficient drug concentration in the target tissue caused by the lack of effective permeation-promoting force in traditional unilateral injection methods, significantly improving the therapeutic efficiency of local drug delivery.

[0024] 2. This invention incorporates a limiting sleeve corresponding to the elastic balloon within the main lumen. The limiting sleeve, in conjunction with the balloon, provides a sealing function and forms a second annular chamber, offering a structural basis for the volume compression of the annular occlusion chamber. The limiting sleeve also restricts the radial internal expansion limit of the elastic balloon, effectively preventing it from collapsing into the main lumen when expanding and compressing the vessel wall, thus ensuring that the main lumen, serving as the drug delivery channel, remains unobstructed in the second state. Furthermore, when the balloon expands, it first forms a sealed contact with the inner walls of these two limiting sleeves, thereby defining the second annular chamber between them. This ensures that the limited amount of drug injected into the annular occlusion chamber is accurately and completely delivered and confined to the predetermined area of ​​action, overcoming the drawback of drug loss in traditional unilateral perfusion therapy.

[0025] 3. This invention incorporates an exudation orifice, which, combined with the expansion process of the push balloon, enables a highly controllable closed-loop drug delivery operation. The exudation orifice ensures that the medication can only leak unidirectionally from the catheter sidewall into the occlusion chamber, avoiding catheter blockage or medication contamination caused by blood backflow. The expansion process of the push balloon is a continuous mechanical sequence, integrating the two treatment steps of medication ejection and medication penetration into an automated operation. This design simplifies the complex drug delivery process to three steps: filling the occlusion unit, injecting medication, and initiating the push program. This significantly reduces reliance on operator experience and hand stability, and significantly improves the repeatability and safety of treatment in small-scale, high-precision interventional procedures. Attached Figure Description

[0026] To more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings used in the description of the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort. Wherein: Figure 1 This is a front view of the assembly structure of the present invention when the sealing unit is in the first state; Figure 2 for Figure 1 A partial cross-sectional view of point A in the middle; Figure 3 for Figure 1 A partial cross-sectional view of point B in the middle section; Figure 4 for Figure 1 A partial cross-sectional view of point C in the middle; Figure 5 This is a front view of the assembly structure of the present invention when the sealing unit is in the second state; Figure 6 for Figure 5 A partial cross-sectional view of point D in the middle; Figure 7 for Figure 5 A partial cross-sectional view of point E in the middle; Figure 8 Front view of the assembly structure of the present invention after the fluid-inflating balloon is inflated; Figure 9 for Figure 8 A partial cross-sectional view of the structure at point F in the middle; In the diagram, 1. Catheter body; 11. Proximal end; 12. Distal end; 121. Elastic balloon; 122. Annular occlusion chamber; 123. First connecting tube; 13. Main lumen; 131. Limiting tube; 132. Fluid-pushing balloon; 133. Second connecting tube; 2. Second annular chamber; 3. Exudation hole; 31. One-way valve; 4. Vessel wall. Detailed Implementation

[0027] The technical solutions of the embodiments of the present invention are clearly and completely described below through specific examples. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Those skilled in the art can easily understand other advantages and effects of the present invention from the content disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments. In the absence of conflict, the following embodiments and features in the embodiments can be combined with each other. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0028] An arterial drug delivery tube, such as Figures 1-9 As shown, it includes: an arterial drug delivery tube comprising: a catheter body 1 having a proximal end 11, a distal end 12, and a main lumen 13 located between the two; an occlusion unit disposed at the distal end 12 of the catheter body 1, and the occlusion unit being configured to operate within the blood vessel from a first state to a second state, wherein in the second state, the occlusion unit at least partially abuts against the vessel wall 4 and blocks blood flow in the corresponding vascular region; and a plurality of exudation holes 3 disposed on the wall of the catheter body 1, the exudation holes 3 being distributed around the central axis of the catheter body 1 to form a circumferential annular array and distributed along the axial direction of the catheter body 1 to form an axial linear array, such that the drug is uniformly injected from multiple positions along the radial direction of the catheter body 1 into the annular occlusion chamber 122, which is beneficial to improving the drug diffusion efficiency; the exudation holes 3 are configured to allow fluid in the main lumen 13 to pass through the wall of the catheter body 1 and leak into the intravascular environment. In the first state, the outer diameter of the catheter body 1 is smaller than the inner diameter of the blood vessel, so that the catheter body 1 can move smoothly from the arterial end to the drug release target area. In the second state, the flow path of the fluid seeping out through the exudation hole 3 is at least partially constrained by the occlusion unit. As the fluid drug gradually passes through the tube wall and enters the intravascular environment, the drug first moves in the annular occlusion chamber 122 and gradually diffuses outward through the blood vessel wall 4.

[0029] This overcomes the problems of severe drug loss, short drug retention time in the target area, and low diffusion efficiency caused by incomplete blood flow isolation in existing unilateral perfusion protocols for local drug delivery.

[0030] By abandoning the static, single-point ligation approach, a dynamically operable occlusion unit is set up to create a relatively isolated fluid environment in the target area. Based on this, the drug is directly released into the isolated vessel segment through the exudation orifice 3. By achieving spatial occlusion and directional drug exudation, a constrained diffusion path is provided for the exudating drug through their synergistic effect, fundamentally improving the effective concentration and duration of the drug's action on the target vessel wall 4.

[0031] In some embodiments of this application, such as Figures 1-9 As shown, the elastic balloon 121 is specifically an annular balloon, constructed as part of the wall of the catheter body 1. In the first state, the outer diameter of the catheter body 1 is substantially uniform. By embedding the elastic balloon 121 within the catheter wall, making it flush with the outer wall of the catheter when not inflated, a smooth and continuous surface is formed. This significantly reduces the frictional force of the catheter when passing through the tortuous sections of the blood vessel, lowering the risk of scratching the vascular intima. This improves catheter permeability and reduces resistance during catheter advancement within the blood vessel, as well as the risk of vascular damage.

[0032] In some embodiments of this application, such as Figures 1-9 As shown, the distal end 12 of the catheter body 1 has a closed, smooth, rounded shape. This prevents the catheter tip from puncturing or damaging blood vessels, especially small and fragile ones, during travel. The rounded shape allows the tip of the catheter body 1 to push away rather than puncture the vessel wall 4 upon contact. This significantly improves the safety of surgery, especially in small laboratory animals, and reduces the risk of complications such as vasospasm, perforation, or dissection.

[0033] In some embodiments of this application, such as Figures 1-9As shown, the exudation hole 3 is located on the catheter body 1 within the axial section corresponding to the annular occlusion chamber 122. By aligning the axial position of the exudation structure with the area between the two elastic balloons 121, the drug is ensured to be precisely released into the target area space defined by the occlusion structure. This achieves a high degree of synergy between the drug release location and the occlusion space, which helps improve treatment accuracy and reduce drug waste.

[0034] In some embodiments of this application, such as Figures 1-9 As shown, the occlusion unit includes at least two elastic balloons 121 spaced apart along the axial direction of the catheter body 1. When the elastic balloons 121 are in their natural state, the occlusion unit is in a first state; when the elastic balloons 121 are inflated, the occlusion unit is in a second state. When both elastic balloons 121 are in the second state, an annular occlusion chamber 122 is formed between the at least two elastic balloons 121, the inner wall of the blood vessel, and the outer wall of the catheter body 1. The exudation hole 3 is in fluid communication with the annular occlusion chamber 122. By constructing a spatially defined and clearly defined local drug retention environment between the catheter and the blood vessel wall 4, the range of drug action can be controlled more precisely. The annular occlusion chamber 122 strictly restricts the drug release area to the area between the two elastic balloons 121, completely avoiding drug loss along the long axis of the blood vessel. This ensures that the drug can only diffuse within this chamber and act on the corresponding segment of the blood vessel wall 4, thereby solving the problem of severe drug loss and difficulty in retention under the action of pulse and blood flow.

[0035] In some embodiments of this application, such as Figures 1-9 As shown, at least two elastic balloons 121 are fluidly connected to a first connecting tube 123. The end of the first connecting tube 123 opposite to the elastic balloons 121 extends towards the proximal end 11 of the catheter body 1 and remains outside through the wall of the catheter body 1. While ensuring the synchronous and reliable operation of the two elastic balloons 121, the internal cavity structure of the catheter is simplified to the maximum extent to reduce manufacturing costs and failure rate. Specifically, by sharing the fluid passage within the first connecting tube 123, the synchronous control of the two elastic balloons 121 is achieved by utilizing the characteristics of fluid pressure transmission.

[0036] In some embodiments of this application, such as Figures 1-9 As shown, the seepage hole 3 is specifically a guide hole with a one-way flow restriction structure. The one-way flow restriction structure is configured to allow fluid to seep out from the main cavity 13 through the guide hole and to inhibit external fluid from flowing back into the main cavity 13 through the guide hole. The one-way flow restriction structure is specifically a one-way valve 31.

[0037] The one-way valve 31 ensures one-way output of the fluid agent. This prevents backflow of blood and impurities, ensures the patency of the main lumen 13 and the exudate orifice 3, and maintains the positive pressure established in the annular occlusion chamber 122 during injection, thereby helping to improve delivery efficiency and drive the drug solution to diffuse more effectively into the blood vessel wall 4 tissue.

[0038] In some embodiments of this application, such as Figures 1-9 As shown, the main cavity 13 is provided with two axially fixed limiting cylinders 131. The axial positions of the two limiting cylinders 131 correspond to the axial positions of the two elastic balloons 121 respectively. The limiting cylinders 131 are configured to restrict the corresponding elastic balloons 121 from collapsing into the main cavity 13 when inflated.

[0039] A rigid or semi-rigid limiting cylinder 131 with axial fixation is used as an internal support framework. When the elastic balloon 121 inflates, its inner side is physically blocked by the limiting cylinder 131, and the inflation force is directed towards the vessel wall 4 on the outer side of the main lumen 13, thereby ensuring the unobstructed flow of the central channel of the main lumen 13. This also prevents the inner wall of the elastic balloon 121 from collapsing towards the center of the main lumen 13 while it radially inflates and compresses the vessel wall 4, thus avoiding blockage of the main lumen 13 and ensuring that the medication can flow smoothly and reach the exudation structure area between the two elastic balloons 121.

[0040] In some embodiments of this application, such as Figures 1-9 As shown, the two limiting cylinders 131 are spaced apart from each other, and a drug storage and delivery area is formed in the main cavity 13 section between the two limiting cylinders 131.

[0041] The space between the two limiting cylinders 131 is structured into a defined second annular chamber 2. This chamber is defined at both ends by the limiting cylinders 131, thus its volume is fixed. This ensures controllable drug dosage injected into this area and matches the external occlusion area. This defines a precisely voluminous drug-containing space within the catheter, providing a structural basis for subsequent drug delivery.

[0042] In some embodiments of this application, such as Figures 1-9As shown, a fluid-push balloon 132 is disposed between two elastic balloons 121, and the fluid-push balloon 132 partially passes through the two limiting cylinders 131; the outer diameter of the fluid-push balloon 132 in its natural state is smaller than the inner diameter of the limiting cylinder 131, and the fluid-push balloon 132 is fluidly connected to a second connecting tube 133; during the process of the fluid-push balloon 132 deforming from its natural state to an inflated state, its outer wall abuts against the inner wall of the limiting cylinder 131, and a second annular chamber 2 is formed between the two limiting cylinders 131 that is not connected to the proximal end 11 of the catheter body 1; the volume of the second annular chamber 2 gradually decreases as the fluid-push balloon 132 continues to deform towards the inflated state, and the drug solution is pushed into the annular sealing chamber 122.

[0043] In some embodiments of this application, such as Figures 1-9 As shown, it also includes a method for intravascular local drug delivery using a delivery tube, which includes the following steps: S1. Deliver the distal end 12 of the catheter body 1 to the target vascular region; S2. By filling the first connecting tube 123 with fluid, the elastic balloon 121 is inflated, thereby forming an annular sealing chamber 122 together with the blood vessel wall 4 inside the blood vessel; S3. Inject fluid agent into the second annular chamber 2 through the main cavity 13; S4. By filling the second connecting pipe 133 with fluid, the fluid-pumping balloon 132 disposed in the second annular chamber 2 is inflated. The inflation of the fluid-pumping balloon 132 performs the following operations in sequence: S401. The outer wall of the push balloon 132 contacts and seals the inner walls of the two limiting cylinders 131, isolating the second annular chamber 2 from the other parts of the main cavity 13; S402. The continuously expanding propellant balloon 132 pushes the fluid agent sealed in the second annular chamber 2 out through the exudation hole 3 into the annular sealing chamber 122; S403. The further expanded propellant balloon 132 contacts and expands the outer wall of the catheter body 1, thereby compressing the volume of the annular occlusion chamber 122 and promoting the diffusion of fluid drugs through the blood vessel wall 4.

[0044] By implementing a three-step operation logic of sealing, ejection, and compression based on the propellant balloon 132, the storage, quantitative ejection, and final permeation enhancement of the drug are integrated into an automated process driven by the expansion of the propellant balloon 132. This ensures that the drug is ejected without backflow in an environment completely isolated from the proximal main lumen 13, and generates controllable local pressure by compressing the sealed chamber, forcing the drug to permeate into the vessel wall 4 tissue, greatly improving delivery efficiency and repeatability. This achieves a highly automated local drug delivery and permeation enhancement process, overcoming the problems of unstable pressure, uneven drug distribution, and low permeation enhancement efficiency associated with manual injection.

[0045] In some embodiments of this application, such as Figures 1-9 As shown, after the inflation of the propellant balloon 132 is performed in operation S403, the procedure further includes: maintaining the propellant balloon 132 in the inflated state for a preset time to maintain the compression state of the annular occlusion chamber 122.

[0046] This setup adds a pressure-holding step after the compression step. By maintaining the expansion of the balloon 132, the annular occlusion chamber 122 is continuously compressed, creating a continuous and stable pressure gradient outside the vessel wall 4. This allows for more effective drug diffusion along the pressure gradient outwards from the vessel wall 4, significantly increasing the drug's penetration depth and retention in the target tissue. Furthermore, it prolongs the duration of the permeation-enhancing pressure generated by compression, ensuring sufficient time for the drug to diffuse across the vessel wall 4 under pressure, rather than rebounding after a momentary pressure release.

[0047] In some embodiments of this application, such as Figures 1-9 Figures 1-9 As shown, after step S403, the procedure further includes: contracting the fluid-injecting balloon 132 and then inflating it again to repeat operations S402 and S403 at least once.

[0048] By introducing a pulsating permeation-enhancing step, after completing one push-compression-holding cycle, the push balloon 132 is reset, allowing a small amount of drug to be replenished into the second annular chamber 2 through the main channel 13, and then the push-compression process is repeated. This pulsating pressure change may better open the intercellular spaces, promote drug penetration, and achieve a more uniform drug distribution. This enables multiple, small-dose pulsating administrations within a single treatment, thereby simulating a drug infusion pattern that is more physiologically consistent and further improving drug penetration efficiency.

Claims

1. An arterial administration line, characterized in that The catheter comprises: a catheter body having a proximal end, a distal end and a main lumen therebetween; a blocking unit arranged at the distal end of the catheter body, and configured to be operable from a first state to a second state in which the blocking unit at least partially abuts against the wall of the blood vessel and blocks the blood flow of the corresponding blood vessel region; a plurality of exuding holes arranged on the wall of the catheter body, and configured to allow the fluid in the main lumen to exude into the intravascular environment through the wall of the catheter body; wherein, when the blocking unit is in the first state, the outer diameter of the catheter body is smaller than the inner diameter of the blood vessel; and when the blocking unit is in the second state, the flow path of the fluid exuding through the exuding holes is at least partially constrained by the blocking unit.

2. An arterial administration line according to claim 1, wherein The blocking unit comprises at least two elastic balloons arranged axially spaced apart along the catheter body, and the blocking unit is in the first state when the elastic balloons are in a natural state, and the blocking unit is in the second state when the elastic balloons are inflated; when the at least two elastic balloons are both in the second state, an annular blocking chamber is formed between the at least two elastic balloons, the intravascular wall and the outer wall of the catheter body, and the exuding holes are in fluid communication with the annular blocking chamber.

3. An arterial administration line according to claim 2, wherein, The at least two elastic balloons are connected in fluid communication with a first communication tube, and the end of the first communication tube away from the elastic balloons extends to the proximal end of the catheter body and is left outside through the wall of the catheter body.

4. The arterial administration line of claim 1, wherein, The exuding hole is specifically a flow guide hole provided with a one-way flow limiting structure configured to allow fluid to exude outward from the main lumen through the flow guide hole, and to inhibit external fluid from flowing reversely into the main lumen through the flow guide hole. The one-way flow limiting structure is specifically a one-way valve.

5. The arterial administration line of claim 2, wherein, The main lumen is provided with two limiting cylinders fixed in position in the axial direction, and the axial positions of the two limiting cylinders correspond to the axial positions of the two elastic balloons respectively, and the limiting cylinders are configured to limit the corresponding elastic balloons from collapsing inward into the main lumen when inflated.

6. An arterial administration line according to claim 5, wherein, The two limiting cylinders are arranged spaced apart from each other, and a medicament storage and delivery region is formed in the section of the main lumen between the two limiting cylinders.

7. An arterial administration line according to claim 6, wherein A liquid pushing balloon is arranged between the two elastic balloons, and the liquid pushing balloon partially penetrates through the two limiting cylinders; the outer diameter of the liquid pushing balloon in the natural state is smaller than the inner diameter of the limiting cylinder, and the liquid pushing balloon is connected in fluid communication with a second communication tube; during the deformation of the liquid pushing balloon from the natural state to an inflated state, the outer wall of the liquid pushing balloon abuts against the inner wall of the limiting cylinder, and a second annular chamber is formed between the two limiting cylinders, which is not in communication with the proximal end of the catheter body; the volume of the second annular chamber gradually decreases during the continuous deformation of the liquid pushing balloon to the inflated state, and the liquid is pushed into the annular blocking chamber.

8. A method of intravascular local administration using the administration tube as claimed in claim 7, characterized in that, The method comprises the following steps: S1. delivering the distal end of the catheter body to the target blood vessel region; S2. inflating the elastic balloons by filling fluid into the first communication tube, so as to form an annular blocking chamber in the blood vessel together with the wall of the blood vessel; S3. Injecting fluid medicament into the second annular chamber through the main lumen; S4. Inflating a liquid pushing balloon arranged in the second annular chamber by filling fluid into a second communicating tube, the inflation of the liquid pushing balloon sequentially performs the following operations: S401. The outer wall of the liquid pushing balloon contacts and seals the inner walls of the two limiting cylinders, isolating the second annular chamber from other parts of the main lumen; S402. The continuously inflated liquid pushing balloon pushes the fluid medicament stored in the second annular chamber out to the annular occlusion chamber through the exudation hole; S403. The further inflated liquid pushing balloon contacts and expands the outer wall of the catheter body, thereby compressing the volume of the annular occlusion chamber and promoting the outward diffusion of the fluid medicament through the blood vessel wall.

9. The method of intravascular local administration according to claim 8, wherein, After the liquid pushing balloon inflates to perform operation S403, further comprising: maintaining the liquid pushing balloon in the inflated state for a preset time to maintain the compression state of the annular occlusion chamber.

10. The method of intravascular local administration according to claim 8 or 9, wherein, After step S403, further comprising: deflating the liquid pushing balloon and then inflating it again to repeat the operations S402 and S403 at least once. S3. Injecting fluid medicament into the second annular chamber through the main lumen; S4. Inflating a liquid pushing balloon arranged in the second annular chamber by filling fluid into a second communicating tube, the inflation of the liquid pushing balloon sequentially performs the following operations: S401. The outer wall of the liquid pushing balloon contacts and seals the inner walls of the two limiting cylinders, isolating the second annular chamber from other parts of the main lumen; S402. The continuously inflated liquid pushing balloon pushes the fluid medicament stored in the second annular chamber out to the annular occlusion chamber through the exudation hole; S403. The further inflated liquid pushing balloon contacts and expands the outer wall of the catheter body, thereby compressing the volume of the annular occlusion chamber and promoting the outward diffusion of the fluid medicament through the blood vessel wall. After the liquid pushing balloon inflates to perform operation S403, further comprising: maintaining the liquid pushing balloon in the inflated state for a preset time to maintain the compression state of the annular occlusion chamber. After step S403, further comprising: deflating the liquid pushing balloon and then inflating it again to repeat the operations S402 and S403 at least once.

Images